Latest Research Evaluating VASCEPA® (Icosapent Ethyl) Mechanisms of Action Presented at European Atherosclerosis Society (EAS) Congress 2020
October 05, 2020 at 07:00 AM EDT
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the presentation of new data at European Atherosclerosis Society (EAS) Congress 2020, being held virtually from October 4 – October 7, 2020 that add to the growing body of knowledge on the potential mechanisms of action of VASCEPA® (icosapent ethyl). These new findings, based on research or analyses supported by Amarin, are being presented in one Science at a Glance presentation and one e-poster presentation by R. Preston Mason, Ph.D., President and Founder of Elucida Research LLC, and Cardiovascular Division, Department of Medicine at the Harvard Medical School-affiliated Brigham and Women's Hospital.
“The full VASCEPA story continues to unfold as we learn more about how eicosapentaenoic acid acts on a cellular level,” said Craig Granowitz, M.D., Ph.D., Amarin’s senior vice president and chief medical officer. “The new data presented at EAS Congress 2020 helps to further understand the unique ways by which VASCEPA lowers persistent cardiovascular risk and helps to address the global impact of cardiovascular disease.”
Key data presented at EAS Congress 2020
“Eicosapentaenoic Acid, but not a Mixed Omega-3 Fatty Acid Supplement, Improved Nitric Oxide Bioavailability in Human Endothelial Cells In Vitro” – presented on behalf of all authors by R. Preston Mason, Ph.D. – October 5, 12:23-12:28 p.m. CEST (Central European Summer Time)
“Eicosapentaenoic Acid (EPA) Containing Phospholipids Modulate Membrane Structure” – presented on behalf of all authors by R. Preston Mason, Ph.D. – available from October 4
Additional information on EAS Congress 2020 can be found at https://eas2020.com/
About Cardiovascular Risk
Controlling bad cholesterol, also known as LDL-C, is one way to reduce a patient’s risk for cardiovascular events, such as heart attack, stroke or death. However, even with the achievement of target LDL-C levels, millions of patients still have significant and persistent risk of cardiovascular events, especially those patients with elevated triglycerides. Statin therapy has been shown to control LDL-C, thereby reducing the risk of cardiovascular events by 25-35%.2 Significant cardiovascular risk remains after statin therapy. People with elevated triglycerides have 35% more cardiovascular events compared to people with normal (in range) triglycerides taking statins.3,4,5
REDUCE-IT, conducted over seven years and completed in 2018, followed 8,179 patients at over 400 clinical sites in 11 countries with the largest number of sites located within the United States. REDUCE-IT was conducted based on a special protocol assessment agreement with FDA. The design of the REDUCE-IT study was published in March 2017 in Clinical Cardiology.6 The primary results of REDUCE-IT were published in The New England Journal of Medicine in November 2018.7 The total events results of REDUCE-IT were published in the Journal of the American College of Cardiology in March 2019.8 These and other publications can be found in the R&D section on the company’s website at www.amarincorp.com.
About VASCEPA® (icosapent ethyl) Capsules
Indications and Limitation of Use
The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.
Important Safety Information
Key clinical effects of VASCEPA on major adverse cardiovascular events are included in the Clinical Studies section of the prescribing information for VASCEPA as set forth below:
Effect of VASCEPA on Time to First Occurrence of Cardiovascular Events in Patients with
Availability of Other Information About Amarin
Amarin Contact Information
Lee M. Stern
1 American Heart Association. Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association. Circulation. 2020;141:e139–e596.